异基因造血细胞或实体器官移植后巨细胞病毒感染患者的治疗模式、医疗资源利用及费用评估

数据集获取（Figshare）

• 源站标题：Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation
• DOI：10.6084/m9.figshare.19306974.v1
• 发布日期：2022-03-04
• 文件数：3 个
• 文件总体积：4.10 MB
• 源站页面：https://tandf.figshare.com/articles/dataset/Evaluation_of_treatment_patterns_healthcare_resource_utilization_and_costs_among_patients_receiving_treatment_for_cytomegalovirus_following_allogeneic_hematopoietic_cell_or_solid_organ_transplantation/19306974

命令行下载

curl -L -o "ijme_a_2046388_sm2066.eps" "https://ndownloader.figshare.com/files/34292430"
curl -L -o "ijme_a_2046388_sm1522.eps" "https://ndownloader.figshare.com/files/34292433"
curl -L -o "ijme_a_2046388_sm1025.pdf" "https://ndownloader.figshare.com/files/34292436"

文件清单

• ijme_a_2046388_sm2066.eps（2.02 MB）
• ijme_a_2046388_sm1522.eps（1.71 MB）
• ijme_a_2046388_sm1025.pdf（364.10 KB）

文件总体积 4.10 MB（源站 API 实测）。

数据说明

Management of cytomegalovirus (CMV) infection/disease in transplant recipients may be complicated by toxicities and resistance to conventional antivirals, adding to the overall healthcare burden. We characterized treatment patterns, healthcare resource utilization (HCRU), and costs to elucidate the healthcare burden associated with CMV therapies post-transplant.
A retrospective, longitudinal cohort study of transplant recipients using data from a US commercial insurance claims database (2013–2017) was conducted. Patients with a claim for post-transplant CMV diagnosis and anti-CMV treatment (ganciclovir, valganciclovir, foscarnet, or cidofovir) were identified (Treated CMV cohort) and compared with patients with neither a claim for CMV diagnosis nor anti-CMV treatment (No CMV cohort) for outcomes including HCRU and associated costs. Allogeneic hematopoietic cell transplantation (HCT) or solid organ transplantation (SOT) recipients were analyzed separately. Anti-CMV treatment patterns were assessed in the Treated CMV cohort. Costs were evaluated among subgroups with myelosuppression or nephrotoxicity.
Overall, 412 allogeneic HCT and 899 SOT patients were included in the Treated CMV cohorts, of which 41.7% and 52.5%, respectively, received multiple antiviral courses. Treated CMV cohorts compared with No CMV cohorts had higher mean monthly healthcare visits per patient (allogeneic HCT: 8.83 vs 6.61, SOT: 5.61 vs 4.45) and had an incremental adjusted mean monthly cost per patient differences of $8,157 (allogeneic HCT, p p Results may not be generalizable to patients covered by government insurance or outside the USA.
CMV post-transplant managed with conventional treatment is associated with substantial HCRU and costs. The burden remains particularly high for patients requiring multiple treatment courses for post-transplant CMV or for transplant recipients who develop myelosuppression or nephrotoxicity.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.19306974.v1（source: https://tandf.figshare.com/articles/dataset/Evaluation_of_treatment_patterns_healthcare_resource_utilization_and_costs_among_patients_receiving_treatment_for_cytomegalovirus_following_allogeneic_hematopoietic_cell_or_solid_organ_transplantation/19306974）。